US6479498B1 - Sodium channel drugs and uses - Google Patents

Sodium channel drugs and uses Download PDF

Info

Publication number
US6479498B1
US6479498B1 US10/039,699 US3969901A US6479498B1 US 6479498 B1 US6479498 B1 US 6479498B1 US 3969901 A US3969901 A US 3969901A US 6479498 B1 US6479498 B1 US 6479498B1
Authority
US
United States
Prior art keywords
compound
ligand
linker
substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/039,699
Other languages
English (en)
Inventor
Daniel Marquess
Seok-Ki Choi
David T. Beattie
John H. Griffin
Scott Armstrong
Timothy J. Church
Thomas E. Jenkins
David C. Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/458,107 external-priority patent/US6420354B1/en
Application filed by Theravance Inc filed Critical Theravance Inc
Priority to US10/039,699 priority Critical patent/US6479498B1/en
Assigned to ADVANCED MEDICINE, INC. reassignment ADVANCED MEDICINE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GREEN, DAVID C.
Assigned to THERAVANCE, INC. reassignment THERAVANCE, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ADVANCED MEDICINE, INC.
Application granted granted Critical
Publication of US6479498B1 publication Critical patent/US6479498B1/en
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC reassignment THERAVANCE BIOPHARMA R&D IP, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THERAVANCE, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
US10/039,699 1999-06-04 2001-11-09 Sodium channel drugs and uses Expired - Lifetime US6479498B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/039,699 US6479498B1 (en) 1999-06-04 2001-11-09 Sodium channel drugs and uses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32556399A 1999-06-04 1999-06-04
US09/458,107 US6420354B1 (en) 1998-06-08 1999-12-08 Sodium channel drugs and uses
US10/039,699 US6479498B1 (en) 1999-06-04 2001-11-09 Sodium channel drugs and uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/458,107 Continuation US6420354B1 (en) 1998-06-08 1999-12-08 Sodium channel drugs and uses

Publications (1)

Publication Number Publication Date
US6479498B1 true US6479498B1 (en) 2002-11-12

Family

ID=26984991

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/039,699 Expired - Lifetime US6479498B1 (en) 1999-06-04 2001-11-09 Sodium channel drugs and uses

Country Status (1)

Country Link
US (1) US6479498B1 (US06479498-20021112-C00020.png)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20050014845A1 (en) * 2003-07-16 2005-01-20 Boehringer Ingelheim International Gmbh Ambroxol for the treatment of epilepsy
US20050049287A1 (en) * 2003-08-29 2005-03-03 Ehring George R. Treating pain using selective antagonists of persistent sodium current
US20050054695A1 (en) * 2003-08-29 2005-03-10 Ehring George R. Treating neurological disorders using selective antagonists of persistent sodium current
US20050197334A1 (en) * 2002-09-26 2005-09-08 Deping Wang Bifunctional heterocyclic compounds and methods of making and using same
US20070048753A1 (en) * 2005-02-17 2007-03-01 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
US20070072811A1 (en) * 2003-03-05 2007-03-29 Farmer Jay J Bifunctional heterocyclic compounds and methods of making and using the same
US20070111943A1 (en) * 2005-09-30 2007-05-17 Mccormack Kenneth Tetrodotoxin-resistant sodium channel alpha subunit
US20070149463A1 (en) * 2003-10-30 2007-06-28 Oyelere Adegboyega K Bifunctional macrolide heterocyclic compounds and methods of making and using the same
US20070270357A1 (en) * 2003-11-18 2007-11-22 Farmer Jay J Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same
US20080045585A1 (en) * 2004-02-27 2008-02-21 Farmer Jay J Macrocyclic Compounds And Methods Of Making And Using The Same
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US20110086589A1 (en) * 2009-10-14 2011-04-14 Alan James Skrepcinski Outdoor communication cabinet including fan tray and filter and method of detecting blockage of communication cabinet filter

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2300543A1 (de) 1973-01-08 1974-07-11 Basf Ag 6700 Ludwigshafen Neue derivate des trimethylphenols und verfahren zu ihrer herstellung
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0372934A2 (en) 1988-12-07 1990-06-13 The Wellcome Foundation Limited Pharmacologically active CNS compounds
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP0459829A1 (en) 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
WO1992005802A1 (en) 1990-09-28 1992-04-16 Neorx Corporation Polymeric carriers for release of covalently linked agents
WO1993004048A1 (de) 1991-08-16 1993-03-04 Boehringer Ingelheim Kg Neue pyrazinderivative, ihre herstellung und verwendung
WO1993006121A1 (en) 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
WO1996020935A1 (en) 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
WO1996020934A1 (en) 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
US5571827A (en) 1990-03-13 1996-11-05 Sepracor Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
WO1997009317A2 (en) 1995-09-05 1997-03-13 Glaxo Group Limited Optically active phenyl pyrimidine derivative as analgesic agent
US5616345A (en) 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
WO1997027169A1 (en) 1996-01-25 1997-07-31 F.Hoffmann-La Roche Ag (2-dimethylphenoxy-1-methylethyl) ethylamine
US5686495A (en) 1991-02-08 1997-11-11 Cambridge Neuroscience, Inc. Substituted hydrazinedicarboximidamides and methods of use thereof
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
WO1998038174A1 (en) 1997-03-01 1998-09-03 Glaxo Group Limited Pyrazine compounds
EP0869119A1 (en) 1997-04-03 1998-10-07 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives being sodium channle blockers
CA2240325A1 (en) 1998-03-27 1998-11-14 Synsorb Biotech, Inc. Methods for screening compound libraries
US5846839A (en) 1995-12-22 1998-12-08 Glaxo Group Limited Methods for hard-tagging an encoded synthetic library
US5891643A (en) 1995-11-14 1999-04-06 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US5985933A (en) 1997-01-24 1999-11-16 Celgene Corporation Methods for treating central and peripheral nerve pain

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2300543A1 (de) 1973-01-08 1974-07-11 Basf Ag 6700 Ludwigshafen Neue derivate des trimethylphenols und verfahren zu ihrer herstellung
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5616345A (en) 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0372934A2 (en) 1988-12-07 1990-06-13 The Wellcome Foundation Limited Pharmacologically active CNS compounds
US5571827A (en) 1990-03-13 1996-11-05 Sepracor Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
EP0459829A1 (en) 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
WO1992005802A1 (en) 1990-09-28 1992-04-16 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5686495A (en) 1991-02-08 1997-11-11 Cambridge Neuroscience, Inc. Substituted hydrazinedicarboximidamides and methods of use thereof
WO1993004048A1 (de) 1991-08-16 1993-03-04 Boehringer Ingelheim Kg Neue pyrazinderivative, ihre herstellung und verwendung
WO1993006121A1 (en) 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
WO1996020935A1 (en) 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
WO1996020934A1 (en) 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
WO1997009317A2 (en) 1995-09-05 1997-03-13 Glaxo Group Limited Optically active phenyl pyrimidine derivative as analgesic agent
US5891643A (en) 1995-11-14 1999-04-06 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US5846839A (en) 1995-12-22 1998-12-08 Glaxo Group Limited Methods for hard-tagging an encoded synthetic library
WO1997027169A1 (en) 1996-01-25 1997-07-31 F.Hoffmann-La Roche Ag (2-dimethylphenoxy-1-methylethyl) ethylamine
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US5985933A (en) 1997-01-24 1999-11-16 Celgene Corporation Methods for treating central and peripheral nerve pain
WO1998038174A1 (en) 1997-03-01 1998-09-03 Glaxo Group Limited Pyrazine compounds
EP0869119A1 (en) 1997-04-03 1998-10-07 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives being sodium channle blockers
CA2240325A1 (en) 1998-03-27 1998-11-14 Synsorb Biotech, Inc. Methods for screening compound libraries

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
*Bernatowicz et al., Tet. Lett. 34(21):3389-3392 (1993).
*Bossert et al., Angew. Chem. Int. Ed. 20:762-769 (1981).
*Brenner et al., PNAS 89:5381-5383 (1992).
*Choi et al., J. Neurosci. 7(2):357-368 (1987).
*Choi, J. Neurosci. 7(2): 369-379 (1987).
*Cole et al., Angew. Chem. Int. Ed. 35(15):1668-1671 (1996).
*Costall et al., Neuropharmacol. 26(2/3):195-200 (1987).
*Dalby et al., Epilepsy Res. 28:63-72 (1997).
*Davis et al., J. Med. Chem. 38(22):4363-4366 (1995).
*Denyer et al., DDT 3(7):323-332 (1998).
*Doggrell et al., Clin. Exp. Pharmacol. Physiol. 21:833-843 (1994).
*Doig et al., J. Chrom. 554(1/2):181-189 (1991).
*Dubuisson et al., Pain 4:161-174 (1977).
*Gee et al., J. Biol. Chem. 273(34):21980-21987 (1998).
*Huettner et al., J. Neurosci. 6(10):3044-3060 (1986).
*Hunter et al., Curr. Opin. Invest. Drugs 1(1):72-81 (1999).
*Hunter et al., Eur. J. Pharmacol. 324:153-160 (1997).
*Kuo et al., Br. J. Pharmacol. 121:1231-1238 (1997).
*Kuo et al., Mol. Pharmacol. 54:712-721 (1998).
*Liang et al., Science 274:1520-1522 (1996).
*Loughhead et al., J. Org. Chem. 64(9):3373-3375 (1999).
*Melchiorre et al., TIPS 10(Suppl):55-59 (1989).
*Menger et al., J. Org. Chem. 60(21):6666-6667 (1995).
*O'Neill et al., Eur. J. Pharmacol. 332:121-131 (1997).
*Portoghese, J. Med. Chem. 35(11):1927-1937 (1992).
*Shepheard et al., Neuropharmacol. 34(3):255-261 (1995).
*Shuker et al., Science 274;1531-1534 (1996).
*Southam et al., Eur. J. Pharmacol. 358:19-24 (1998).
*Ther et al., Deutsche Apotheker-Zeitung 103(17):514-420 (1963) (w/English summary).
*Whalley et al., PACE 18(Part I):1686-1704 (1995).

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264385A1 (en) * 2002-09-26 2006-11-23 Deping Wang Bifunctional heterocyclic compounds and methods of making and using same
US7335753B2 (en) 2002-09-26 2008-02-26 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US20050197334A1 (en) * 2002-09-26 2005-09-08 Deping Wang Bifunctional heterocyclic compounds and methods of making and using same
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
WO2004066990A3 (en) * 2003-01-30 2004-11-04 Dynogen Pharmaceuticals Inc Methods of treating lower urinary tract disorders using sodium channel modulators
WO2004066990A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20050107353A1 (en) * 2003-01-30 2005-05-19 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using losigamone
US20070072811A1 (en) * 2003-03-05 2007-03-29 Farmer Jay J Bifunctional heterocyclic compounds and methods of making and using the same
US20050014845A1 (en) * 2003-07-16 2005-01-20 Boehringer Ingelheim International Gmbh Ambroxol for the treatment of epilepsy
US20050054695A1 (en) * 2003-08-29 2005-03-10 Ehring George R. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US20060287366A1 (en) * 2003-08-29 2006-12-21 Ehring George R Treating pain using selective antagonists of persistent sodium current
US20060287399A1 (en) * 2003-08-29 2006-12-21 Ehring George R Treating pain using selective antagonists of persistent sodium current
US8153645B2 (en) 2003-08-29 2012-04-10 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US8124612B2 (en) 2003-08-29 2012-02-28 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7705055B2 (en) 2003-08-29 2010-04-27 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7767718B2 (en) 2003-08-29 2010-08-03 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US20050049287A1 (en) * 2003-08-29 2005-03-03 Ehring George R. Treating pain using selective antagonists of persistent sodium current
US7728034B2 (en) 2003-08-29 2010-06-01 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US20070149463A1 (en) * 2003-10-30 2007-06-28 Oyelere Adegboyega K Bifunctional macrolide heterocyclic compounds and methods of making and using the same
US20070270357A1 (en) * 2003-11-18 2007-11-22 Farmer Jay J Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same
US20080045585A1 (en) * 2004-02-27 2008-02-21 Farmer Jay J Macrocyclic Compounds And Methods Of Making And Using The Same
US8841263B2 (en) 2004-02-27 2014-09-23 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US8202843B2 (en) 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US20110117112A1 (en) * 2005-02-17 2011-05-19 Vertex Pharmaceuticals Incorporated Sodium channel protein type iii alpha-subunit splice variant
US7915385B2 (en) 2005-02-17 2011-03-29 Vertex Pharmaceuticals Incorporated Sodium channel protein type III α-subunit splice variant
US20090264623A1 (en) * 2005-02-17 2009-10-22 Vertex Pharmaceuticals Sodium channel protein type iii alpha-subunit splice variant
US20070048753A1 (en) * 2005-02-17 2007-03-01 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
US8252541B2 (en) 2005-02-17 2012-08-28 Vertex Pharmaceuticals Incorporated Sodium channel protein type III α-subunit splice variant
US8663936B2 (en) 2005-02-17 2014-03-04 Vertex Pharmaceuticals Incorporated Sodium channel protein type III α-subunit splice variant
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20070111943A1 (en) * 2005-09-30 2007-05-17 Mccormack Kenneth Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US20110086589A1 (en) * 2009-10-14 2011-04-14 Alan James Skrepcinski Outdoor communication cabinet including fan tray and filter and method of detecting blockage of communication cabinet filter

Similar Documents

Publication Publication Date Title
US6420354B1 (en) Sodium channel drugs and uses
EP1085890A1 (en) Novel sodium channel drugs and uses
WO1999063984A9 (en) Novel sodium channel drugs and uses
US6288055B1 (en) Analgesic agents
US6897305B2 (en) Calcium channel drugs and uses
CA2319120A1 (en) Phosphodiesterase-v modulator drugs and their uses
US6479498B1 (en) Sodium channel drugs and uses
US6420560B1 (en) H1—histamine receptor antagonists
WO1999064050A9 (en) Novel potassium channel drugs and their uses
US7101909B2 (en) Calcium channel drugs and uses
ZA200004562B (en) Novel sodium channel drugs and uses.
WO1999063992A1 (en) Novel calcium channel drugs and uses

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED MEDICINE, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREEN, DAVID C.;REEL/FRAME:012497/0032

Effective date: 20011107

AS Assignment

Owner name: THERAVANCE, INC., CALIFORNIA

Free format text: MERGER;ASSIGNOR:ADVANCED MEDICINE, INC.;REEL/FRAME:013017/0267

Effective date: 20020403

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERAVANCE, INC.;REEL/FRAME:033162/0611

Effective date: 20140601